Home > Insider Trading > Filing (0001209191-14-076513)

Filing Details

Accession Number:: 0001209191-14-076513
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-12-18 08:52:44
Reporting Period:: 2014-12-15

Filing Date:: 2014-12-18
Accepted Time:: 2014-12-18 08:52:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
858803	Avanir Pharmaceuticals Inc.	AVNR	Pharmaceutical Preparations (2834)	330314804

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1314596	Keith Katkin	30 Enterprise Suite 400 Aliso Viejo CA 92656	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2014-12-15	20,000	$16.95	976,769	No	4	S	Direct
Common Stock	Acquisiton	2014-12-15	139,200	$1.74	1,115,969	No	4	M	Direct
Common Stock	Acquisiton	2014-12-15	55,960	$1.29	1,171,929	No	4	M	Direct
Common Stock	Disposition	2014-12-15	195,160	$16.95	976,769	No	4	S	Direct
Common Stock	Disposition	2014-12-17	62,520	$16.93	914,249	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2014-12-15	55,960	$0.00	55,960	$1.29
Common Stock	Stock Option (right to buy)	Disposition	2014-12-15	139,200	$0.00	139,200	$1.74

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
976,769		2017-03-21	No	4	M	Direct
976,769		2019-11-27	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Action of 1934, as amended. A portion of the proceeds from the sales will be used to pay required withholdings due by the Reporting Person for vesting RSUs. Following the sales reported on this Form 4, the Reporting Person has a total of 1,278,556 options to purchase shares of common stock that are vested and immediately exercisable and a total of 290,625 options to purchase shares of common stock that have not yet vested. Following the sales reported on this Form 4, the Reporting Person also has 734,202 unvested Restricted Stock Units, of which 140,611 are performance-based Restricted Stock Units.
Represents the weighted-average price at which shares were sold within a range between $16.905 and 16.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Includes previously reported shares of common stock underlying Restricted Stock Grants granted to the Reporting Person, which are subject to certain vesting conditions.
Represents the weighted-average price at which shares were sold within a range between $16.89 and 16.98. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Represents the weighted-average price at which shares were sold within a range between $16.93 and 16.935. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
The option was granted on 3/21/2007 and vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.
The option was granted on 11/27/2009 and vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.